SPECIALTY QUANTITY LIMIT PROGRAM

IDHIFA (enasidenib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	FDA-recommended dosing	Standard Limit
ldhifa (enasidenib) 100 mg tablet	 Acute myeloid leukemia: The recommended dose is 100 mg orally once daily. Dose modifications: For elevation of bilirubin greater than 3 times the upper limit of normal sustained for ≥ 2 weeks without elevated transaminases or other hepatic disorders: Reduce Idhifa dose to 50 mg daily. Resume Idhifa at 100 mg daily if bilirubin elevation resolves to less than 2 times upper limit of normal For Grade 3 or higher toxicity considered related to treatment including tumor lysis syndrome (not including differentiation syndrome and noninfectious leukocytosis): Interrupt Idhifa until toxicity resolves to Grade 2 or lower. Resume Idhifa at 50 mg daily; may increase to 100 mg daily if toxicities resolve to Grade 1 or lower. 	30 tablets per 30 days
ldhifa (enasidenib) 50 mg tablet		30 tablets per 30 days

III. REFERENCE

1. Idhifa [package insert]. Summit, NJ: Celgene Corporation; August 2017.

Specialty Quantity Limit Idhifa P2017.docx

© 2017 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.